7 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 6 with minor changes only.
Primary completion pushed from May 15, 2027 to Sep 30, 2028
Also in this update: Primary endpoint(s) modified; Study completion pushed from Jul 15, 2027 to Mar 30, 2030
Revolution Medicines, Inc.Phase 1/2 NCT06445062 Registry history of NCT06445062 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 93 → 98 locations
Revolution Medicines, Inc.Phase 1/2 NCT06162221 Registry history of NCT06162221 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 5 locations
Revolution Medicines, Inc.Phase 3 NCT07805954 Registry history of NCT07805954 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 13 → 19 locations
And 1 more change in the last 30 days
Revolution Medicines, Inc.Phase 3 NCT07621718 Registry history of NCT07621718 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 61 → 82 locations
And 1 more change in the last 30 days
Revolution Medicines, Inc.Phase 3 NCT07491445 Registry history of NCT07491445 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 153 → 158 locations
Revolution Medicines, Inc.Phase 3 NCT06881784 Registry history of NCT06881784 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 74 → 78 locations
Revolution Medicines, Inc.Phase 3 NCT07252232 Registry history of NCT07252232 on ClinicalTrials.gov (opens the registry)
| Phase 1 | 3 | |
| Phase 1/2 | 5 | |
| Phase 3 | 7 |
Pancreatic Cancer (11) · Lung Cancer (9) · Non-Small Cell Lung Cancer (NSCLC) (9) · Colorectal Cancer (7) · Endometrial Cancer (2) · Esophageal Cancer (2) · Gastric Cancer (2) · Ovarian Cancer (2) · Melanoma (1)